University of California, Davis activated as a Clinical Trial Site for Ongoing Ph 1 CERTAIN-T Trial of CER-1236 in Hematologic Malignancies
“Activating UC Davis as a clinical site is a meaningful operational milestone for CERo and for the CERTAIN-T study,” said Kent Cunningham, Chief Executive Officer of SRX Global. “Bringing manufacturing and patient enrollment together at a single, highly regarded academic institution, streamlines logistics while strengthening the overall clinical trial footprint. This progress reinforces our conviction in CERo’s differentiated approach to engineered T cell therapeutics, and we look forward to continuing to support the team as we work toward closing the proposed acquisition.”
Share:
More News
“The positive outcome of our pre-IND interactions with the FDA reinforces the development pathway for MaaT034 and supports its continued advancement toward the clinic. It also represents an important step in MaaT Pharma’s expansion into immuno-oncology, highlighting the broader potential of our first in class co-cultivated microbiome donor-independent platform across
“Patients with metastatic RAS G12D non-squamous NSCLC, occurring in approximately 4% of cases, represent an underserved population, with no approved targeted treatment options. Initial clinical data evaluating zoldonrasib in combination with standard of care pembrolizumab and platinum doublet chemotherapy in patients with previously untreated metastatic RAS G12D non-squamous NSCLC showed
“At Georgiamune, we are focused on uncovering novel mechanisms that control immune-cell function and translating that biology into first-in-class medicines across autoimmune disease and oncology,” said Samir N. Khleif, M.D., Founder and Chief Executive Officer of Georgiamune. “GIM-621 is one of multiple programs to emerge from that work, alongside three
“Our team’s outstanding execution has enabled us to rapidly advance three programs into the clinic in 2026 and make significant progress in developing next-generation IO, ADC and combination therapies. Together with our partner, Kelun-Biotech, we have achieved seven IND clearances to date, and by mid-2027, we expect more than 2,000